Pure Bioscience Probability of Future Pink Sheet Price Finishing Under 0.08

PUREDelisted Stock  USD 0.09  0.03  26.83%   
Pure Bioscience's future price is the expected price of Pure Bioscience instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Pure Bioscience performance during a given time horizon utilizing its historical volatility. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
  
Please specify Pure Bioscience's target price for which you would like Pure Bioscience odds to be computed.

Pure Bioscience Target Price Odds to finish below 0.08

The tendency of Pure Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 0.08  or more in 90 days
 0.09 90 days 0.08 
nearly 4.03
Based on a normal probability distribution, the odds of Pure Bioscience to drop to $ 0.08  or more in 90 days from now is nearly 4.03 (This Pure Bioscience probability density function shows the probability of Pure Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Pure Bioscience price to stay between $ 0.08  and its current price of $0.0878 at the end of the 90-day period is about 5.78 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.42 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Pure Bioscience will likely underperform. Additionally Pure Bioscience has an alpha of 0.2529, implying that it can generate a 0.25 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Pure Bioscience Price Density   
       Price  

Predictive Modules for Pure Bioscience

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pure Bioscience. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.080.090.09
Details
Intrinsic
Valuation
LowRealHigh
0.080.080.10
Details

Pure Bioscience Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Pure Bioscience is not an exception. The market had few large corrections towards the Pure Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pure Bioscience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pure Bioscience within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.25
β
Beta against Dow Jones1.42
σ
Overall volatility
0.02
Ir
Information ratio 0.02

Pure Bioscience Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pure Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pure Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Pure Bioscience is not yet fully synchronised with the market data
Pure Bioscience has some characteristics of a very speculative penny stock
Pure Bioscience has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K.
Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 41.0% of the company outstanding shares are owned by corporate insiders

Pure Bioscience Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pure Pink Sheet often depends not only on the future outlook of the current and potential Pure Bioscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pure Bioscience's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding88 M

Pure Bioscience Technical Analysis

Pure Bioscience's future price can be derived by breaking down and analyzing its technical indicators over time. Pure Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Pure Bioscience. In general, you should focus on analyzing Pure Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Pure Bioscience Predictive Forecast Models

Pure Bioscience's time-series forecasting models is one of many Pure Bioscience's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Pure Bioscience's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Pure Bioscience

Checking the ongoing alerts about Pure Bioscience for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Pure Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Pure Bioscience is not yet fully synchronised with the market data
Pure Bioscience has some characteristics of a very speculative penny stock
Pure Bioscience has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K.
Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 41.0% of the company outstanding shares are owned by corporate insiders
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Pure Pink Sheet

If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation